Study to ONO-4538 in Patients With Rhabdoid Tumor
ConditionRhabdoid Tumor
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age1+
SponsorOno Pharmaceutical Co., Ltd.
About this trial
Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors
Eligibility criteria
Qualifiers
Gender: Not specified
Age (at the time of consent): 1 year or older
Patients who are refractory or intolerant to one or more regimens of chemotherapy for rhabdoid Tumors
Patients with advanced or recurrent rhabdoid Tumors not eligible for curative resection
Disqualifiers
Patients with a history of active concurrent malignancy or complications
Patients with spinal lesions expected to require radiation therapy or surgical intervention during the trial period
Patients with concomitant central nervous system disorders other than AT/RT that are inadequately controlled or may lead to discontinuation of the investigational drug
Trial design
Treatments tested in this trial
- ONO-4538
Treatment groups
23 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov